Search Results

Changes in circulating tumor DNA levels quickly predict how patients with diffuse large B cell lymphoma are responding to therapy, according to a Stanford-led study. Currently, patients wait months for the results.

Bereaved mother Mycah Clemons raised money for a summer scholarship at Stanford for research on diffuse intrinsic pontine glioma. The move sparked a series of experiments that have led to a possible treatment for the tumor.

In mice, a fatal brainstem tumor was cleared by injecting it with engineered T cells that recognized the cancer and targeted it for destruction. The Stanford discovery is moving to human trials.

Analyzing individual cancer cells has enabled Stanford researchers to identify the small population of cells that spur relapse in some children with leukemia.

Priming the immune system with induced pluripotent stem cells prevented or slowed the development of cancer in mice, Stanford researchers found.

Stanford scientists have developed a biochemical screen that identifies molecules critical to immunotherapy for a host of diseases, including cancer.

High-grade gliomas, a group of aggressive brain tumors, cease growing in mice if a signaling molecule called neuroligin-3 is absent or its activity is blocked with drugs, a Stanford team has shown.

Targeting backup biological pathways often used by cancers can lead to more efficient drug development and less-toxic therapies. Stanford researchers have developed a new way to identify these pathways.

Stanford cancer researchers Ronald Levy and Howard Chang have been named Outstanding Investigators by the National Cancer Institute. They were awarded grants of up to $7 million over six years to advance their studies.

Antibodies against the CD47 “don’t eat me” signal were shown in mice to be a safe and effective way to target five kinds of pediatric brain tumors, according to Stanford researchers.